CCL5 and benign prostatic hyperplasia: The testosterone group and ATGSE-treated group at the doses of 250 and 500 mg/kg, compared to BPH + GSE 500 mg/kg group resulted in a significant reduction of the following mediators: IL-1ra (p ≤ 0.0001), KC(p ≤ 0.0001), JE (p ≤ 0.0001), and MIP-2 (p ≤ 0.0001) and M-SFC (p ≤ 0.0001 for 250 mg/kg and p ≤ 0.05 for 500 mg/kg), whereas a prominent reduction of BLC (p ≤ 0.0001), C5a (p ≤ 0.0001), G-CSF (p ≤ 0.0001), and RANTES (p ≤ 0.0001) mediators was observed only at the dose of 250 mg/kg.